M. El-Gaby, S. Abdel Gawad, M. Ghorab, et al., “Synthesis and Biological Activity of Some Novel Thieno[2,3-d]quinpline, Quinoline[3,2:4,5]thieno[3,2-d]pyrimidine and Pyrido[2,3:4,5]thieno[2,3-d]quinoline Derivatives,” Phosphorus, Sulphur, Silicon and Related Elements, Vol. 181, No. 2, 2006, pp. 279-297.
 V. V. Kouznetsov, C. O. Puentes, A. R. R. Bohorques, S. A. Zacchino, M. Sortino, M. Gupta, et al., “A Straightforward Synthetic Approach to Antitumoral Pyridinyl Substituted 7H-Indino [2,1-C] Quinoline Derivatives via Three-Component Imino Diels-Alder Reaction,” Letters in Organic Chemistry, Vol. 3, No. 4, 2006, pp. 300-304. doi:10.2174/157017806776114595
 G. Bouchain, S. Leit, S. Frechette, E. A. Khalil, R. Lavoie, O. Moradei, S. H. Woo, M. Fournel. P. T. Yan, A. Kalita, M. C. Trachy-Bourget, C. Beaulieu, M. F. Robert, A. R. MacLeod, J. M. Besterman and D. Delorme, “Development of Potential Antitumor Agents. Synthesis and Biological Evaluation of a New Set of Sulfonamide Derivatives as Histone Deacetylase Inhibitors,” Journal of Medicinal Chemistry, Vol. 46, No. 5, 2003, pp. 820-830. doi:10.1021/jm020377a
 P. W. Finn, M. Bandara, C. Butcher, A. Finn, R. Hollinshead, N. Khan, N. Law, S. Murthy, R. Romero and C. Watkins, “Novel Sulfonamide Derivatives as Inhibitors of Histone Deacetylase,” Helvetica Chimica Acta, Vol. 88, No. 7, 2005, pp. 1630-1657. doi:10.1002/hlca.200590129
 M. M. Ghorab, F. A. Ragab, E. Noaman, H. I. Heiba and E. M. El-Hossary, “Synthesis of Some Novel Quinolines and Pyrimido [4,5-B] Quinolines Bearing a Sulfonamide Moiety as Potential Anticancer and Radioprotective Agents,” Arzneimittelforschung, Vol. 57, No. 12, 2007, pp. 795-803.
 L. Hu, Z. R. Li, J. D. Jiang and D. W. Boykin, “Novel Diaryl or Heterocyclic Sulfonamides as Antimitotic Agents. Anti-Cancer Agents in Medicinal Chemistry,” Anti-Cancer Agents in Medicinal Chemistry, Vol. 8, No. 7, 2008, pp. 739-745.
 M. Fournel, M. C. Trachy-Bourget, P. T. Yan, A. Kalita, C. Bonfils, C. Beaulieu, S. Frechette, S. Leit, E. Abou-Khalil, S. H. Woo, D. Delorme, A. R. MacLeod, J. M. Besterman and Z. Li, “Sulfonamide Anilides, a Novel Class of Histone Deacetylase Inhibitors, Are Antiproliferative against Human Tumors,” Cancer Research, Vol. 62, No. 15, 2002, pp. 4325-4330.
 K. B. Glaser, M. J. Staver, J. F. Waring, J. Stender, R. G. Ulrich and S. K. Davidsen, “Gene Expression Profiling of Multiple Histone Deacetylase (HDAC) Inhibitors: Defining a Common Gene Set Produced by HDAC Inhibition in T24 and MDA Carcinoma Cell Lines,” Molecular Cancer Therapeutics, Vol. 2, No. 2, 2003, pp. 151-163.
 L. C. Hsi, X. Xi, R. Lotan, I. Shureiqi and S. M. Lippman, “The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Induces Apoptosis via Induction of 15-lipoxygenase-1 in Colorectal Cancer Cells,” Cancer Research, Vol. 64, No. 23, 2004, pp. 8778-8781. doi:10.1158/0008-5472.CAN-04-1867
 S. Sakajiri, T. Kumagai, N. Kawamata, T. Saitoh, J. W. Said and H. P. Koeffler, “Histone Deacetylase Inhibitors Profoundly Decrease Proliferation of Human Lymphoid Cancer Cell Lines,” Experimental Hematology, Vol. 33, No. 1, 2005, pp. 53-61. doi:10.1016/j.exphem.2004.09.008
 C. Zhang, V. Richon, X. Ni, R. Talpur and M. Duvic, “Selective Induction of Apoptosis by Histone Deacetylase Inhibitor SAHA in Cutaneous T-Cell Lymphoma Cells: Relevance to Mechanism of Therapeutic Action,” Journal of Investigative Dermatology, Vol. 125, No. 5, 2005, pp. 1045-1052. doi:10.1111/j.0022-202X.2005.23925.x
 M. Entin-Meer, X. Yang, S. R. V. Berg, K. R. Lamborn, A. Nudelman, A. Rephaeli and D. A. Haas-Kogan, “In Vivo Efficacy of a novel Histone Deacetylase Inhibitor in Combination with Radiation for the Treatment of Gliomas,” Neuro-Oncology, Vol. 9, No. 2, 2007, pp. 82-88. doi:10.1215/15228517-2006-032
 M. Entin-Meer, A. Rephaeli, X. Yang, A. Nudelman, S. R. Vandenberg and D. A. Haas-Kogan, “Butyric Acid Prodrugs Are Histone Deacetylase Inhibitors That Show Antineoplastic Activity and Radiosensitizing Capacity in the Treatment of Malignant Gliomas,” Molecular Cancer Therapeutics, Vol. 4, No. 12, 2005, pp. 1952-1961. doi:10.1158/1535-7163.MCT-05-0087
 K. Camphausen, D. Cerna, T. Scott, M. Sproull, W. E. Burgan, M. A. Cerra, H. Fine and P. J. Tofilon, “Enhancement of in Vitro and in Vivo Tumor Cell Radiosensitivity by Valproic Acid,” International Journal of Cancer, Vol. 114, No. 3, 2005, pp. 380-386. doi:10.1002/ijc.20774
 A. Munshi, J. F. Kurland, T. Nishikawa, T. Tanaka, M. L. Hobbs, S. L. Tucker, S. Ismail, C. Stevens and R. E. Meyn, “Histone Deacetylase Inhibitors Radiosensitize Human Melanoma Cells by Suppressing DNA Repair Activity,” Clinical Cancer Research, Vol. 11, 2005, pp. 4912-4922. doi:10.1158/1078-0432.CCR-04-2088
 Y. Zhang, M. Jung, A. Dritschilo and M. Jung, “Enhancement of Radiation Sensitivity of Human Squamous Carcinoma Cells by Histone Deacetylase Inhibitors,” Radiation Research, Vol. 161, No. 916, 2004, pp. 667-674.
 M. Gupta, U. K. Mazumder, R. S. Kumar and T. S. Kumar, “Antitumor Activity and Antioxidant Role of Bauhinia Racemosa against Ehrlich Ascites Carcinoma in Swiss Albino Mice,” Acta Pharmacologica Sinica, Vol. 25, No. 8, 2004, pp. 1070-1076.
 F. M. Freimoser, C. A. Jakob, M. Aebi and U. Tuor, “The MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide] Assay Is a Fast and Reliable Method for Colorimetric Determination of Fungal Cell Densities,” Applied and Environmental Microbiology, Vol. 65, No. 8, 1999, pp. 3727-3729.
 J. A. Nagle, Z. Ma, M. A. Byrne, M. F. White and L. M. Shaw, “Involvement of Insulin Receptor Substrate 2 in Mammary Tumor Metastasis,” Molecular and Cellular Biology, Vol. 24, No. 22, 2004, pp. 9726-9735. doi:10.1128/MCB.24.22.9726-9735.2004
 D. Baidyaroy, G. Brosch, S. Graessle, P. Trojer and J. D. Walton, “Characterization of Inhibitor-Resistant Histone Deacetylase Activity in Plant-Pathogenic Fungi,” Eukaryotic Cell, Vol. 1, No. 4, 2002, pp. 538-547. doi:10.1128/EC.1.4.538-547.2002
 B. B. Mishell, S. M. Shiiqi, C. Henry, E. L. Chen, J. North, R. Gallily, M. Slomich, K. Miller, J. Marbrook, D. Parks and A. H. Good, “Selected Methods in Cellular Immunology,” W. H. Freeman, San Francisco, 1980, pp. 21-22.
 Y. H. Choi, L. Zhang, W. H. Lee and K. Y. Park, “Genistein-Induced G2/M Arrest Is Associated with the Inhibition of Cyclin B1 and the Induction of p21 in Human Breast Carcinoma Cells,” International Journal of Oncology, Vol. 13, No. 2, 1998, pp. 391-396.
 S. E. Touma, J. S. Goldberg, P. Moench, et al., “Retinoic Acid and the Histone Deacetylase Inhibitor Trichostatin a Inhibit the Proliferation of Human Renal Cell Carcinoma in a Xenograft Tumor Model,” Clinical Cancer Research, Vol. 11, No. 9, 2005, pp. 3558-3662.
 D. Z. Qian, X. Wang, S. K. Kachhap, et al., “The Histone Deacetylase Inhibitor NVP-LAQ824 Inhibits Angiogenesis and Has a Greater Antitumor Effect in Combination With the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor,” Cancer Research, Vol. 64, No. 18, 2004, pp. 6626-6634. doi:10.1158/0008-5472.CAN-04-0540
 K. Camphausen, T. Scott, M. Sproull and P. J. Tofilon, “Enhancement of Xenograft Tumor Radiosensitivity by the Histone Deacetylase Inhibitor MS-275 and Correlation with Histone Hyperacetylation,” Clinical Cancer Research, Vol. 10, 2004, pp. 6066-6071. doi:10.1158/1078-0432.CCR-04-0537
 J. A. Plumb, P. W. Finn, R. J. Williams, et al., “Pharmacodynamic Response and Inhibition of Growth of Human Tumor Xenografts by the Novel Histone Deacetylase Inhibitor PXD101,” Molecular Cancer Therapeutics, Vol. 2, No. 8, 2003, pp. 721-728.
 Y. Komatsu, K. Y. Tomizaki, M. Tsukamoto, et al., “Cyclic Hydroxamicacid-Containing Peptide 31, a Potent Synthetic Histone Deacetylase Inhibitor with Antitumor Activity,” Cancer Research, Vol. 61, 2001, pp. 4459-4466.
 N. Takai, J. C. Desmond, T. Kumagai, et al., “Histone Deacetylase Inhibitors Have a Profound Antigrowth Activity in Endometrial Cancer Cells,” Clinical Cancer Research, Vol. 10, 2004, pp. 1141-1149. doi:10.1158/1078-0432.CCR-03-0100
 J. J. Buggy, Z. A. Cao, K. E. Bass and E. Verner, “CRA-024781: A Novel Synthetic Inhibitor of Histone Deacetylase Enzymes with Antitumor Activity in Vitro and in Vivo,” Molecular Cancer Therapeutics, Vol. 5, 2006, pp. 1309-1317. doi:10.1158/1535-7163.MCT-05-0442
 P. Rocchi, C. Camerin, S. Purgato, R. Fronza, F. Bianucci, F. Guerra, A. Pession and A. M. Ferreri, “p21Waf1/Cip1 Is a Common Target Induced by Short-Chain Fatty Acid HDAC Inhibitors (Valproic Acid, Tributyrin and Sodium Butyrate) in Neuroblastoma Cells,” Oncology Reports, Vol. 13, No. 6, 2005, pp. 1139-1144.
 N. K. Mukhopadhyay, E. Weisberg, D. Gilchrist, R. Bueno, D. J. Sugarbaker and M. T. Jaklitsch, “Effectiveness of Trichostatin A as a Potential Candidate for Anticancer Therapy in Non-Small-Cell Lung Cancer,” The Annals of Thoracic Surgery, Vol. 81, No. 3, 2006, pp. 1034-1042. doi:10.1016/j.athoracsur.2005.06.059
 R. S. Kumar, B. Jayakar and B. Rajkapoor, “Antitumor Activity of Indigofera Trita on Ehrlich Ascites Carcinoma Induced Mice,” International Journal of Cancer Research, Vol. 3, No. 4, 2007, pp. 180-185. doi:10.3923/ijcr.2007.180.185
 P. Gallinari, S. Di Marco, P. Jones, M. Pallaoro and C. Steinkuhler, “HDACs, Histone Deacetylation and Gene Transcription: From Molecular Biology to Cancer Therapeutics,” Cell Research, Vol. 17, No. 3, 2007, pp. 195-211.
 V. Baradari, A. Huether, M. Hopfner, D. Schuppan and H. Scherubl, “Antiproliferative and Proapoptotic Effects of Histone Deacetylase Inhibitors on Gastrointestinal Neuroendocrine Tumor Cells,” Endocrine-Related Cancer, Vol. 13, No. 4, 2006, pp. 1237-1250. doi:10.1677/erc.1.01249
 C. J. Phiel, F. Zhang, E. Y. Huang, M. G. Guenther, M. A. Lazar and P. S. Klein, “Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen,” Journal of Biological Chemistry, Vol. 276, No. 39, 2001, pp. 36734-36741. doi:10.1074/jbc.M101287200
 M. C. Myzak and R. H. Dashwood, “Histone Deacetylases as Targets for Dietary Cancer Preventive Agents: Lessons Learned with Butyrate, Diallyl Disulfide, and Sulforaphane,” Current Drug Targets, Vol. 7, No. 4, 2006, pp. 443-452. doi:10.2174/138945006776359467
 M. S. Finnin, J. R. Donigian, A. Cohen, V. M. Richon, R. A. Rifkind, P. A. Marks, R. Breslow and N. P. Pavletich, “Structures of a Histone Deacstylase Homologue Bound to the TSA and SAHA Inhibitors,” Nature, Vol. 401, 1999, pp. 188-193. doi:10.1038/43710
 X. Liu, P. Li, P. Widlak, H. Zou, X. Luo, W. T. Garrard and X. Wang, “The 40-kDa Subunit of DNA Fragmentation Factor Induces DNA Fragmentation and Chromatin Condensation during Apoptosis,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 95, No. 925, 1998, pp. 8461-8466.
 M. Enari, H. Sakahira, H. Yokoyama, K. Okawa, A. Iwamatsu and S. Nagata, “A Caspase-Activated DNase that Degrades DNA during Apoptosis, and Its Inhibitor ICAD,” Nature, Vol. 391, 1998, pp. 43-50. doi:10.1038/34112
 D. A. Hsia, S. K. Mitra, C. R. Hauck, D. N. Streblow, J. A. Nelson, D. Ilic, S. Huang, E. Li, G. R. Nemerow, J. Leng, K. S. Spencer, D. A. Cheresh and D. D. Schlaepfer, “Differential Regulation of Cell Motility and Invasion by FAK,” Journal of Cell Biology, Vol. 160, No. 5, 2003, pp. 753-767.
 F. Abel, R. M. Sjoberg, C. Krona, S. Nilsson and T. Martinsson, “Mutations in the N-Terminal Domain of DFF45 in a Primary Germ Cell Tumor and in Neuroblastoma Tumors,” International Journal of Oncology, Vol. 25, No. 5, 2004, pp. 1297-1302.
 G. Driessens, L. Harsan, P. Browaeys, X. Giannakopoulos, T. Velu and C. Bruyns, “Assessment of in Vivo Chemotherapy-Induced DNA Damage in a p53-Mutated Rat Tumor by Micronuclei Assay,” Annals of the New York Academy of Sciences, Vol. 1010, 2003, pp. 775-779. doi:10.1196/annals.1299.139
 P. Widlak, J. Lanuszewska, R. B. Cary and W. T. Garrard, “Subunit Structures and Stoichiometries of Human DFF Proteins before and after Induction of Apoptosis,” Journal of Biological Chemistry, Vol. 278, No. 29, 2003, pp. 26915-26922. doi:10.1074/jbc.M303807200
 H. Kamitani, S. Taniura, K. Watanabe, M. Sakamoto, T. Watanabe and T. Eling, “Histone Acetylation May Suppress Human Glioma Cell Proliferation When p21WAF/ Cip1 and Gelsolin Are Induced,” Neuro Oncology, Vol. 4, 2002, pp. 95-101.
 Y. Higuchi, “Chromosomal DNA Fragmentation in Apoptosis and Necrosis Induced by Oxidative Stress,” Biochemical Pharmacology, Vol. 66, No. 8, 2003, pp. 1527-1535. doi:10.1016/S0006-2952(03)00508-2
 J. L. Aron, M. R. Parthun, G. Marcucci, S. Kitada, A. P. Mone, M. E. Davis, T. Shen, T. Murphy, J. Wickham, C. Kanakry, D. M. Lucas, J. C. Reed, M. R. Grever and J. C. Byrd, “Depsipeptide (FR901228) Induces Histone Acetylation and Inhibition of Histone Deacetylase in Chronic Lymphocytic Leukaemia Cells Concurrent with Activation of Caspase 8-Mediated Apoptosis and Down-Regulation of C-FLIP Protein,” Blood, Vol. 102, No. 2, 2003, pp. 652-658. doi:10.1182/blood-2002-12-3794
 F. Guo, C. Sigua, J. Tao, P. Bali, P. George, Y. Li, S. Wittmann, L. Moscinski, P. Atadja and K. Bhalla, “Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2l/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells,” Cancer Research, Vol. 64, 2004, pp. 2580-2589. doi:10.1158/0008-5472.CAN-03-2629
 R. R. Rosato, J. A. Almenara and S. Grant, “The Histone Deacetylase Inhibitor MS-275 Promotes Differentiation or Apoptosis in Human Leukemia Cells through a Process Regulated by Generation of Reactive Oxygen Species and Induction of p21CIP1/WAF1,” Cancer Research, Vol. 63, 2003, pp. 3637-3645.
 E. S. Arner and A. Holmgren, “Physiological Functions of Thioredoxin and Thioredoxin Reductase,” European Journal of Biochemistry, Vol. 267, No. 20, 2000, pp. 6102-6109. doi:10.1046/j.1432-1327.2000.01701.x
 S. Y. Archer, J. Johnson, H. J. Kim, Q. Ma, H. Mou, V. Daesety, S. Meng and R. A. Hodin, “The Histone Deacetylase Inhibitor Butyrate Down Regulates Cyclin B1 Gene Expression via a p21/WAF-1-Dependent Mechanism in Human Colon Cancer Cells,” American Journal of Physiology—Gastrointestinal and Liver Physiology, Vol. 289, No. 4, 2005, pp. 696-703.
 Y. X. Chen, J. Y. Fang, J. Lu and D. K. Qiu, “Regulation of Histone Acetylation on the Expression of Cell Cycle-Associated Genes in Human Colon Cancer Cell Lines,” Chinese Medical Journal, Vol. 84, No. 4, 2004, pp. 312-317.
 L. Geng, K. C. Cuneo, A. Fu, T. Tu, P. W. Atadja and D. E. Hallahan, “Histone Deacetylase (HDAC) Inhibitor LBH589 Increases Duration of γ-H2AX Foci and Confines HDAC4 to the Cytoplasm in Irradiated Non–Small Cell Lung Cancer,” Cancer Research, Vol. 66, No. 23, 2006, p. 11298. doi:10.1158/0008-5472.CAN-06-0049
 I. A. Kim, J. H. Shin, Il H. Kim, J. H. Kim, J. S. Kim, H. G. Wu, E. K. Chi, S. W. Ha, C. I. Park and G. D. Kao, “Histone Deacetylase Hong Gyun Wu, Inhibitor Mediated Radio Sensitization of Human Cancer Cells: Class Differences and the Potential Influence of p53,” Clinical Cancer Research, Vol. 12, No. 3, 2006, p. 940. doi:10.1158/1078-0432.CCR-05-1230
 K. Camphausen, W. Burgan, M. Cerra, K. A. Oswald, J. B. Trepel, M. J. Lee and P. J. Tofilon. “Enhanced Radiationinduced Cell Killing and Prolongation of γH2AX Foci Expression by the Histone Deacetylase Inhibitor MS-275,” Cancer Research, Vol. 64, 2004, pp. 316-321. doi:10.1158/0008-5472.CAN-03-2630
 J. Joseph, N. Wajapeyee and K. Somasundaram, “Role of p53 Status in Chemosensitivity Determination of Cancer Cells against Histone Deacetylase Inhibitor Sodium Butyrate,” International Journal of Cancer, Vol. 115, No. 1, 2005, pp. 11-18. doi:10.1002/ijc.20842
 S. J. Collis, M. J. Swartz, W. G. Nelson and T. L. DeWeese, “Enhanced Radiation and Chemotherapy-Mediated Cell Killing of Human Cancer Cells by Small Inhibitory RNA Silencing of DNA Repair Factors,” Cancer Research, Vol. 63, 2003, pp. 1550-1554.
 S. Omori, Y. Takiguchi, A. Suda, T. Sugimoto, H. Miyazawa, Y. Takiguchi, N. Tanabe, K. Tatsumi, H. Kimura, P. E. Pardington, F. Chen, D. J. Chen and T. Kuriyama, “Suppression of a DNA Doublestrand Break Repair Gene, Ku70, Increases Radio- and Chemosensitivity in a Human Lung Carcinoma Cell Line,” DNA Repair, Vol. 1, No. 4, 2002, pp. 299-310. doi:10.1016/S1568-7864(02)00006-X
 E. Marangoni, N. Foray, M. O’Driscoll, S. Douc-Rasy, J. Bernier, J. Bourhis, P. Jeggo, “A Ku80 Fragment with Dominant Negative Activity Imparts a Radiosensitive Phenotype to CHO-K1 Cells,” Nucleic Acids Research, Vol. 28, 2000, pp. 4778-4782.